STOCK TITAN

Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Palatin Technologies, Inc. (NYSE American: PTN) will release its Q1 fiscal year 2024 operating results on November 14, 2023, followed by a conference call and live audio webcast. The call will provide an update on the company's development programs and a review of its operating results.
Positive
  • None.
Negative
  • None.

CRANBURY, N.J., Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

Q1 Fiscal Year 2024 Results Press Release 

11/14/2023 at 7:30 a.m. ET



Q1 Fiscal Year 2024 Conference Call-Live 

11/14/2023 at 11:00 a.m. ET

     US Toll Free Dial-In Number:

1-888-506-0062

     International Dial-In Number: 

1-973-528-0011

     Participant Access Code:  

651512



Q1 Fiscal Year 2024 Conference Call-Replay

11/14/2023-11/28/2023

     US Toll Free Dial-In Number:   

1-877-481-4010

     International Dial-In Number: 

1-919-882-2331

     Participant Access Code:  

49457

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-first-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be-held-on-november-14-2023-301983033.html

SOURCE Palatin Technologies, Inc.

FAQ

What is the date of Palatin Technologies, Inc.'s Q1 fiscal year 2024 operating results release?

Palatin Technologies, Inc. will release its Q1 fiscal year 2024 operating results on November 14, 2023.

What time is the conference call and live audio webcast for Palatin Technologies, Inc.'s Q1 fiscal year 2024 operating results?

The conference call and live audio webcast will be held on November 14, 2023, at 11:00 a.m. ET.

How can I access the audio webcast and replay for Palatin Technologies, Inc.'s Q1 fiscal year 2024 operating results?

The audio webcast and replay can be accessed by logging on to the 'Investors-Webcasts' section of Palatin's website at http://www.palatin.com or by clicking the provided link.

Palatin Technologies, Inc.

NYSE:PTN

PTN Rankings

PTN Latest News

PTN Stock Data

32.27M
15.54M
3.35%
10.72%
9.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CRANBURY

About PTN

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy